对比阿柏西普!默沙东全球首创眼科双抗启动首个II/III期研究

医药魔方Info
Feb 28

2月27日,美国临床试验收录网站显示,默沙东的眼科双抗tiespectus(EYE201/MK-8748)启动头对头II/III期研究(MK-8748-002)。tiespectus是EyeBiotech(已被默沙东收购)开发的一款靶向Tie-2(具有免疫球蛋白样和EGF样结构域2的酪氨酸激酶)和VEGF的双抗药物。该研究是一项随机、双盲、多中心临床试验(n=960),旨在评估tiespectus...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10